Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jun;55(6):2601-5.
doi: 10.1128/AAC.01765-10. Epub 2011 Mar 21.

Steady-state Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults

Affiliations
Free PMC article
Clinical Trial

Steady-state Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults

Manjunath P Pai et al. Antimicrob Agents Chemother. .
Free PMC article

Abstract

Voriconazole is an antifungal agent that is currently used as primary therapy for invasive aspergillosis and as a potential treatment for systemic candidiasis. Data on the dosing of voriconazole in obese patients are not available, which is problematic given the increased prevalence of this special population. To address this limitation, we evaluated the steady-state plasma pharmacokinetics of voriconazole through a two-way, crossover design in a cohort of eight healthy volunteers with class II obesity or greater. The median (minimum, maximum) age, weight, and body mass index of obese subjects were 43 (22, 48) years, 133 (105, 155) kg, and 46.2 (38.4, 53.7) kg/m², respectively. The geometric mean ratios (90% confidence intervals) for the area under the curve from time zero to 12 h (dosing interval; AUC(0-τ)), maximum concentration (C(max)), minimum concentration at 12 h (C(min)), and time to C(max) (T(max)) of the 300-mg to 200-mg dosing regimens were 2.0 (1.5, 2.7), 1.8 (1.4, 2.2), 2.2 (1.6, 2.9), and 1.6 (1.0, 2.4) in obese subjects, respectively. The AUC(0-τ) values observed in obese subjects were comparable to those from a historical data set of nonobese subjects. Voriconazole dose-normalized AUC(0-τ) values had a modestly better correlation with lean body weight (r² = 0.42) than total body weight (r² = 0.14). An excellent linear relationship (r² = 0.96) was identified between C(min) values and AUC(0-τ) values. Adjustment of voriconazole doses in individuals with class II obesity or greater does not appear to be necessary on the basis of body weight.

Figures

Fig. 1.
Fig. 1.
Individual voriconazole steady-state concentration-time profiles for obese subjects over the dosing interval by the oral dose regimen.
Fig. 2.
Fig. 2.
Scatter and linear fit plots of AUC0–τ (mg · h/liter) compared to the dose (200 mg or 300 mg) indexed to the individual subject's total body weight (A) or lean body weight (B).
Fig. 3.
Fig. 3.
Scatter and linear fit plots of AUC0–τ (mg · h/liter) compared to the Cmin (mg/liter) of voriconazole.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

Publication types

Feedback